We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00153140
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : February 7, 2013
Information provided by:
Braintree Laboratories

Brief Summary:
The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.

Condition or disease Intervention/treatment Phase
Constipation Drug: polyethyleneglycol3350 Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 239 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
Study Start Date : July 2004
Primary Completion Date : October 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
Drug Information available for: Macrogol
U.S. FDA Resources

Primary Outcome Measures :
  1. A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria

Secondary Outcome Measures :
  1. Analysis of individual ROME I criteria
  2. Safety (adverse event review)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Male or female outpatients at least 18 years of age
  • Constipated according to ROME I criteria
  • If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, double- barrier method, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study
  • Are otherwise in good health, as judged by a physical examination
  • In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent

Exclusion Criteria:

  • Patients with heme positive stool at screening that is not associated with hemorrhoids or anal fissures.
  • Patients with hypo- or hyperthyroidism as determined by medical history.
  • Patients with severe renal impairment.
  • Patients with moderate or severe hepatic impairment.
  • Patients with known or suspected perforation or obstruction.
  • History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
  • Patients with symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.
  • Patients with a known history of organic cause for their constipation.
  • Patients currently taking, or planning to take any of the following medications that are known to effect bowel habits:

    • Antidiarrheals
    • Antacids containing magnesium or aluminum salts
    • Anticholinergics
    • Antispasmodic agents
    • Erythromycin and other macrolides
    • Octreotide
    • Lotronex, Zofran, or other 5-HT3 antagonists
    • Zelnorm, or other 5-HT4 agonists
    • Opiods/narcotic analgesics
    • Prokinetics
    • Serotonin re-uptake inhibitors or tricyclic antidepressants
    • Calcium antagonists
  • Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
  • Female patients of childbearing potential who refuse a pregnancy test.
  • Patients with a known allergy to tegaserod (or any of its excipients) or polyethyleneglycol.
  • Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Patients who, within the past 30 days have participated in an investigational clinical study.
  • Patients that have undergone a colonoscopy within 30 days of screening
  • Patients that are currently taking, or have previously been treated with polyethyleneglycol3350 or tegaserod.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00153140

  Show 25 Study Locations
Sponsors and Collaborators
Braintree Laboratories
Principal Investigator: Jorge Herrera, MD University of South Alabama

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00153140     History of Changes
Other Study ID Numbers: 851-ZCC
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: February 7, 2013
Last Verified: February 2013

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Polyethylene glycol 3350
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Gastrointestinal Agents